Erika is joined by Quintin Maidment, a vice president at CTRx Pathways, to discuss why diversity is critical in clinical drug trials and what barriers stand in the way. In the Beyond the News segment, Nick and Shawn discuss the controversy around efforts by Johnson & Johnson to create a rebate program around 340B drug pricing.